December 14
2:00 pm - 3:00 pm EST

LOCAL TIME

New data: Predict breast cancer treatment response and recurrence risk with ctDNA

This webinar will explore the rapidly evolving role of circulating tumor DNA (ctDNA) in predicting therapy response and disease recurrence in patients with breast cancer, with significant applications for biopharma drug development and clinical practice.

Our expert speakers will discuss the latest 2022 data from SABCS, ASCO, and AACR. This will be followed by a panel discussion on the future directions and implications that can be derived from ctDNA data.

Topics include:
  • Latest I-SPY2 data demonstrating association of pathological complete response (pCR), residual cancer burden (RCB), and ctDNA; Early clearance of ctDNA (at 3 weeks) was associated with a reduced risk of recurrence
  • Latest data from the BELLINI study suggesting that early ctDNA dynamics after 4 weeks of treatment is associated with RECIST response, and may further risk stratify with stable disease
  • Update on surveillance monitoring and treat on molecular relapse, including:
    • (1) An initial readout of LEADER, a ctDNA-guided, randomized Phase II clinical trial of CDK4/6 inhibitor Ribociclib patients for the treatment of ER-positive breast cancer, and
    • (2)The full data set from EBLIS, the largest breast cancer cohort with the longest monitoring of patients with ctDNA (up to 12 years), demonstrating that serial post-operative ctDNA analysis has strong prognostic value
  • Clinical trial designs that enroll patients identified by ctDNA to be at high risk of recurrence or progression, to enable treatment at a time of lower disease burden
  • Use of real-world data to inform the design of ctDNA-guided clinical trials

register now
register for the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Minetta Liu

Minetta Liu

Chief Medical Officer, Natera

Dr. Minetta Liu, MD joined Natera in 2022 as its new Chief Medical Officer (CMO) of oncology.

Dr. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic. In her role at Mayo, she also held a dual appointment in the Department of Laboratory Medicine and Pathology and served as co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine.

Dr. Liu brings a wealth of experience in developing blood-based biomarkers to predict treatment benefits and outcomes in solid tumors and in developing novel therapeutics to improve survival, with a particular focus on breast cancer.

She chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology. She also co-chaired the Correlative Science Working Group and led several multi-institutional clinical trials through the Translational Breast Cancer Research Consortium.

Dr. Liu received her B.A. from Princeton University, her M.D. from Jefferson Medical College and completed her residency and hematology/oncology fellowship at Georgetown University Medical Center.

Angel Rodriguez

Angel Rodriguez

Oncology Medical Director, Natera

Angel Augusto Rodriguez, MD, is a board-certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.

John Simmons
moderator

John Simmons

Global VP Biopharma, Natera

John Simmons, Ph.D. currently leads oncology biopharma partnerships at Natera. Before joining Natera, John completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx). He received his Ph.D. in Tumor Biology from Georgetown University.